VDJ-028

N/A

Report date: 2025/06/09 17:26:45

Base Information

Drug NameVDJ-028
Drug Alias NameVDJ028VDJ-028
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTumor necrosis factor superfamily member 15 modulatorsInterleukin-23 subunit p19 inhibitors
TargetsTumor necrosis factor superfamily member 15Interleukin-23 subunit p19
Therapy Area/IndicationsAtherosclerosisPulmonary Subvalvular StenosisRenal Insufficiency, Chronic +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeijing Vdjbio Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Vdjbio Co Ltd
Inactive CompaniesN/A
Active IndicationsAtherosclerosisPulmonary Subvalvular StenosisRenal Insufficiency, Chronic +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A